Anavex Life Sciences Corp. (AVXL)
1.82
-0.07
(-3.70%)
USD |
NASDAQ |
Oct 02, 16:00
1.815
0.00 (0.00%)
After-Hours: 20:00
Anavex Life Sciences Enterprise Value : 50.38M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 50.38M |
| October 01, 2026 | 56.87M |
| September 30, 2026 | 68.92M |
| September 29, 2026 | 100.44M |
| September 28, 2026 | 99.51M |
| September 25, 2026 | 102.29M |
| September 24, 2026 | 98.58M |
| September 23, 2026 | 99.51M |
| September 22, 2026 | 110.64M |
| September 21, 2026 | 104.15M |
| September 18, 2026 | 106.00M |
| September 17, 2026 | 105.07M |
| September 16, 2026 | 100.44M |
| September 15, 2026 | 107.85M |
| September 14, 2026 | 122.69M |
| September 11, 2026 | 124.54M |
| September 10, 2026 | 128.25M |
| September 09, 2026 | 136.59M |
| September 08, 2026 | 145.86M |
| September 04, 2026 | 146.79M |
| September 03, 2026 | 145.86M |
| September 02, 2026 | 149.57M |
| September 01, 2026 | 147.71M |
| August 31, 2026 | 141.22M |
| August 28, 2026 | 158.84M |
| Date | Value |
|---|---|
| August 27, 2026 | 171.82M |
| August 26, 2026 | 182.01M |
| August 25, 2026 | 211.67M |
| August 24, 2026 | 169.96M |
| August 21, 2026 | 182.01M |
| August 20, 2026 | 171.82M |
| August 19, 2026 | 195.92M |
| August 18, 2026 | 178.30M |
| August 17, 2026 | 179.23M |
| August 14, 2026 | 180.16M |
| August 13, 2026 | 184.79M |
| August 12, 2026 | 197.77M |
| August 11, 2026 | 207.04M |
| August 10, 2026 | 195.92M |
| August 07, 2026 | 191.28M |
| August 06, 2026 | 185.72M |
| August 05, 2026 | 178.30M |
| August 04, 2026 | 173.67M |
| August 03, 2026 | 155.13M |
| July 31, 2026 | 136.59M |
| July 30, 2026 | 131.96M |
| July 29, 2026 | 112.49M |
| July 28, 2026 | 119.90M |
| July 27, 2026 | 113.42M |
| July 24, 2026 | 104.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.834B |
| Oncolytics Biotech, Inc. | 74.98M |
| Sangamo Therapeutics, Inc. | 52.85M |
| Sarepta Therapeutics, Inc. | 2.106B |
| Anixa Biosciences, Inc. | 87.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 7.824M |
| Total Expenses (Quarterly) | -7.824M |
| EPS Diluted (Quarterly) | 0.0842 |
| Earnings Yield | -8.33% |
| Normalized Earnings Yield | -8.330 |